Irbesartán Stada (Irbesartan)

Irbesartan works by selectively blocking the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands, and kidney cells. This inhibition prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vessel relaxation, reduced sodium‑water retention, and lower blood pressure.

The dose of Irbesartán Stada is individualized by the prescribing clinician based on the patient’s blood pressure, kidney function, and overall health status. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk and it is contraindicated during pregnancy. Limited data are available for breastfeeding; therefore, the drug should be used only if the potential benefit justifies the potential risk to the infant.

To order Irbesartán Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers similar blood‑pressure‑lowering efficacy to ACE inhibitors but with a lower incidence of cough and angioedema. Both classes block the renin‑angiotensin system, yet ARBs act downstream at the AT1 receptor, providing an alternative when ACE inhibitors are not tolerated.

Irbesartán Stada tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Irbesartán Stada is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.

The most serious adverse reactions include angioedema (swelling of the face, lips, tongue or throat), acute kidney injury, and severe liver dysfunction. Patients should seek immediate medical attention if they experience swelling, sudden loss of kidney function, or signs of liver trouble such as jaundice.

Irbesartán Stada should not be used by individuals who are pregnant, have known hypersensitivity to irbesartan or any ARB component, or have severe hepatic impairment. Caution is also advised for patients with bilateral renal artery stenosis or those on concurrent high‑dose potassium‑sparing agents.